Literature DB >> 17914554

Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.

Estrid V S Høgdall1, Lise Christensen, Claus K Høgdall, Jan Blaakaer, Simon Gayther, Ian J Jacobs, Ib Jarle Christensen, Susanne K Kjaer.   

Abstract

Estrogen and progesterone are important hormones secreted by the ovary acting through specific receptors. Tumor tissue expression profiles of these have demonstrated prognostic value in malignancies such as breast, uterine and prostate cancer. In this study, including tissue samples from 773 Danish patients with an ovarian tumor, we evaluated whether estrogen receptor (ER) and progesterone receptor (PR) expression correlated with clinico-pathological parameters, and a possible prognostic impact on ovarian cancer (OC) patients was investigated. Using tissue array and immunohistochemistry, we analyzed the ER and PR expression levels in tissues from 582 women with OC and 191 women with low malignancy potential (LMP) ovarian tumors. Our results demonstrated that ER was expressed in 30 of the 191 LMP tumors (16%) and in 207 of the 582 OC (36%). PR was expressed in 38 LMP tumors (20%) and in 115 OC (20%). For both tumor types an excess of positive tumors was found in the serous compared to the mucinous subtype (p< or =0.00001). The frequency of ER expression-positive OC increased with increasing FIGO stage (p=0.0003), and the frequency of PR-positive tumors increased with increasing histological grade (p=0.0006). In a Cox survival analysis, a tissue ER and PR expression 10% or higher was found to imply an independent significant advantageous course of patient disease-specific survival (ER: hazard ratio (HR), 0.80; 95% confidence interval (CI), 0.63-0.99; PR: HR, 0.69; 95% CI, 0.51-0.94) together with FIGO stage, residual tumor after primary surgery, age at diagnosis and other histological types vs. serous adenocarcinoma. The histological grade of tumor was found to have no independent prognostic value. The prognostic value of ER and PR was found additive with a HR for patients with high ER and PR expression of 0.48 (95% CI, 0.31-0.74) compared to patients with <10% expression for both receptors. In conclusion, our results predict that an elevated expression of ER and PR, alone and in combination, point to a favorable outcome for patients with OC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914554

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  52 in total

1.  Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.

Authors:  David M Gershenson; Charlotte C Sun; Revathy B Iyer; Anais L Malpica; John J Kavanagh; Diane C Bodurka; Kathleen Schmeler; Michael Deavers
Journal:  Gynecol Oncol       Date:  2012-03-06       Impact factor: 5.482

2.  Recurrent epithelial ovarian cancer and hormone therapy.

Authors:  Yoshihito Yokoyama; Hideki Mizunuma
Journal:  World J Clin Cases       Date:  2013-09-16       Impact factor: 1.337

Review 3.  Progesterone action in breast, uterine, and ovarian cancers.

Authors:  Caroline H Diep; Andrea R Daniel; Laura J Mauro; Todd P Knutson; Carol A Lange
Journal:  J Mol Endocrinol       Date:  2015-01-13       Impact factor: 5.098

4.  Host CYP27A1 expression is essential for ovarian cancer progression.

Authors:  Sisi He; Liqian Ma; Amy E Baek; Anna Vardanyan; Varsha Vembar; Joy J Chen; Adam T Nelson; Joanna E Burdette; Erik R Nelson
Journal:  Endocr Relat Cancer       Date:  2019-07       Impact factor: 5.678

5.  Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ERα expression in high-grade serous ovarian carcinoma.

Authors:  Ye Han; Yongkun Wei; Jun Yao; Yu-Yi Chu; Chia-Wei Li; Jennifer L Hsu; Lei Nie; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2020-04-01       Impact factor: 6.166

Review 6.  Hormonal treatment in recurrent and metastatic gynaecological cancers: a review of the current literature.

Authors:  Dirkje W Sommeijer; Katrin M Sjoquist; Michael Friedlander
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

7.  Validation of tissue microarray technology in ovarian cancer: results from the Nurses' Health Study.

Authors:  Jonathan L Hecht; Joanne Kotsopoulos; Margaret A Gates; Susan E Hankinson; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

8.  Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming.

Authors:  Caroline H Diep; Todd P Knutson; Carol A Lange
Journal:  Mol Cancer Res       Date:  2015-11-17       Impact factor: 5.852

9.  Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the Nurses' Health Study.

Authors:  Jonathan L Hecht; Joanne Kotsopoulos; Susan E Hankinson; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-04-21       Impact factor: 4.254

10.  Polymorphisms of glutathione S-transferase π 1 and toll-like receptors 2 and 9: Association with breast cancer susceptibility.

Authors:  Mohammad F Al-Harras; Maha E Houssen; Mohamed E Shaker; Kamel Farag; Omar Farouk; Rehan Monir; Rasha El-Mahdy; Ekbal M Abo-Hashem
Journal:  Oncol Lett       Date:  2016-01-28       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.